Hebei Senlang Biotechnology Inc., Ltd.
Hebei Senlang Biotechnology Inc., Ltd.
Explore linked clinical trials.14 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| CLL-1-Targeted In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory Acute Myeloid Leukemia | Disease Attributes, Hemic and Lymphatic Diseases, Inflammation, Neoplasm, Residual, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Shock, Systemic Inflammatory Response Syndrome, acute myeloid leukemia, cytokine release syndrome, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Not yet recruiting | Phase 1 | 2026-10-02 | NCT07841002 | |
| In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 | 2026-08-20 | NCT07775508 | |
| Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T-cell non-Hodgkin lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-05-07 | NCT06874946 | |
| Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-03-30 | NCT06880913 | |
| Autologous CAR-T Cell Therapy for Refractory and Relapsing Ulcerative Colitis: A Single-Center Exploratory Study | UC | Recruiting | Early phase 1 | 2026-02-27 | NCT07435779 | |
| Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial. | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Not yet recruiting | Phase 1 / Phase 2 | 2026-02-19 | NCT07421856 | |
| SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma | Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Not yet recruiting | Early phase 1 | 2026-02-10 | NCT07234721 | |
| Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL | B-ALL | Recruiting | Phase 2 | 2025-11-24 | NCT07244406 | |
| Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL. | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T lymphoblastic leukemia/lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Not yet recruiting | Phase 2 | 2025-11-24 | NCT07244380 | |
| Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases | autoimmune disease, immune system disorder | Not yet recruiting | Phase 1 / Phase 2 | 2025-09-08 | NCT07161193 | |
| The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Not applicable | 2025-06-24 | NCT05618041 | |
| To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors | 19 and 20+ B Cell Hematologic Tumors; 19 and 22+ B Cell Hematologic Tumors | Recruiting | Phase 1 | 2025-06-18 | NCT05388695 | |
| CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T-lymphoblastic lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 | 2023-11-18 | NCT06136364 | |
| Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Not applicable | 2022-11-25 | NCT05626400 |